TerminatedNot Applicable

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Stopped: The study was terminated due to low participant enrolment and to accommodate PYC's future interventional study.

United States, Australia, Austria1 participantsStarted 2024-02-28

Plain-language summary

The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.

Who can participate

Age range

8 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Female volunteers must:
. Male volunteers must:

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Best-corrected High Contrast Visual Acuity (HCVA)

Timeframe: Baseline through Year 2

Low Contrast Visual Acuity (LCVA)

Timeframe: Screening through Year 2

Contrast Sensitivity

Timeframe: Baseline through Year 2

Color Vision

Timeframe: Baseline through Year 2

Retinal Thickness

Timeframe: Baseline through Year 2

Ellipsoid Zone (EZ) Volume

Timeframe: Baseline through Year 2

Ellipsoid Zone (EZ) Area

Timeframe: Baseline through Year 2

Visual Field Sensitivity

Timeframe: Baseline through Year 2

Trial details

NCT IDNCT06140329

SponsorPYC Therapeutics

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-03-01

View on ClinicalTrials.gov More Autosomal Dominant Optic Atrophy trials

What they're measuring

Best-corrected High Contrast Visual Acuity (HCVA)

Timeframe: Baseline through Year 2

Low Contrast Visual Acuity (LCVA)

Timeframe: Screening through Year 2

Contrast Sensitivity

Timeframe: Baseline through Year 2

Color Vision

Timeframe: Baseline through Year 2

Retinal Thickness

Timeframe: Baseline through Year 2

Ellipsoid Zone (EZ) Volume

Timeframe: Baseline through Year 2

Ellipsoid Zone (EZ) Area

Timeframe: Baseline through Year 2

Visual Field Sensitivity

Timeframe: Baseline through Year 2